129 related articles for article (PubMed ID: 25388236)
1. Expression of cadherin 17 in well-differentiated neuroendocrine tumours.
Snow AN; Mangray S; Lu S; Clubwala R; Li J; Resnick MB; Yakirevich E
Histopathology; 2015 Jun; 66(7):1010-21. PubMed ID: 25388236
[TBL] [Abstract][Full Text] [Related]
2. NKX6-1 Is a Novel Immunohistochemical Marker for Pancreatic and Duodenal Neuroendocrine Tumors.
Tseng IC; Yeh MM; Yang CY; Jeng YM
Am J Surg Pathol; 2015 Jun; 39(6):850-7. PubMed ID: 25871618
[TBL] [Abstract][Full Text] [Related]
3. Tissue-specific cadherin CDH17 is a useful marker of gastrointestinal adenocarcinomas with higher sensitivity than CDX2.
Panarelli NC; Yantiss RK; Yeh MM; Liu Y; Chen YT
Am J Clin Pathol; 2012 Aug; 138(2):211-22. PubMed ID: 22904132
[TBL] [Abstract][Full Text] [Related]
4. Expression of the intestinal transcription factor CDX2 in carcinoid tumors is a marker of midgut origin.
Jaffee IM; Rahmani M; Singhal MG; Younes M
Arch Pathol Lab Med; 2006 Oct; 130(10):1522-6. PubMed ID: 17090195
[TBL] [Abstract][Full Text] [Related]
5. Immunoreactivity of HOXB13 in Neuroendocrine Neoplasms Is a Sensitive and Specific Marker of Rectal Well-Differentiated Neuroendocrine Tumors.
Soukup J; Manethova M; Stejskal V; Hornychova H; Cesak T; Netuka D; Ryska A; Gabalec F
Endocr Pathol; 2023 Sep; 34(3):333-341. PubMed ID: 37552455
[TBL] [Abstract][Full Text] [Related]
6. Islet 1 (Isl1) expression is a reliable marker for pancreatic endocrine tumors and their metastases.
Schmitt AM; Riniker F; Anlauf M; Schmid S; Soltermann A; Moch H; Heitz PU; Klöppel G; Komminoth P; Perren A
Am J Surg Pathol; 2008 Mar; 32(3):420-5. PubMed ID: 18300808
[TBL] [Abstract][Full Text] [Related]
7. CDX-2 homeobox gene product expression in neuroendocrine tumors: its role as a marker of intestinal neuroendocrine tumors.
Barbareschi M; Roldo C; Zamboni G; Capelli P; Cavazza A; Macri E; Cangi MG; Chilosi M; Doglioni C
Am J Surg Pathol; 2004 Sep; 28(9):1169-76. PubMed ID: 15316316
[TBL] [Abstract][Full Text] [Related]
8. Positivity for SATB2 distinguishes Islet1 positive rectal neuroendocrine tumours from pancreaticoduodenal neuroendocrine tumours.
Mohanty SK; Tiwari A; Bhardwaj N; Chuang F; Kim E; Lugo H; Yuan X; Diffalha SA; Peralta-Venturina M; Balzer B; Dhall D
J Clin Pathol; 2021 Sep; 74(9):582-588. PubMed ID: 32934105
[TBL] [Abstract][Full Text] [Related]
9. A clinicopathological study on the expression of cadherin-17 and caudal-related homeobox transcription factor (CDX2) in human gastric carcinoma.
Ge J; Chen Z; Wu S; Yuan W; Hu B; Chen Z
Clin Oncol (R Coll Radiol); 2008 May; 20(4):275-83. PubMed ID: 18353622
[TBL] [Abstract][Full Text] [Related]
10. SATB2 protein expression by immunohistochemistry is a sensitive and specific marker of appendiceal and rectosigmoid well differentiated neuroendocrine tumours.
Hoskoppal D; Epstein JI; Gown AM; Arnold Egloff SA; Gordetsky JB; Shi CJ; Giannico GA
Histopathology; 2020 Mar; 76(4):550-559. PubMed ID: 31595536
[TBL] [Abstract][Full Text] [Related]
11. SATB2 is a sensitive marker for lower gastrointestinal well-differentiated neuroendocrine tumors.
Li Z; Yuan J; Wei L; Zhou L; Mei K; Yue J; Gao H; Zhang M; Jia L; Kang Q; Huang X; Cao D
Int J Clin Exp Pathol; 2015; 8(6):7072-82. PubMed ID: 26261600
[TBL] [Abstract][Full Text] [Related]
12. CDH17 Is a More Sensitive Marker for Gastric Adenocarcinoma Than CK20 and CDX2.
Altree-Tacha D; Tyrrell J; Haas T
Arch Pathol Lab Med; 2017 Jan; 141(1):144-150. PubMed ID: 28029907
[TBL] [Abstract][Full Text] [Related]
13. The expression of TTF1, CDX2 and ISL1 in 74 poorly differentiated neuroendocrine carcinomas.
Lee H; Fu Z; Koo BH; Sheehan CE; Young GQ; Lin J; Patil DT; Yang Z
Ann Diagn Pathol; 2018 Dec; 37():30-34. PubMed ID: 30236546
[TBL] [Abstract][Full Text] [Related]
14. CDH17+/CDX2+ Can be Helpful in Providing Support for Small Intestinal Origin Versus Pancreatic or Biliary Origin.
Ma H; Xiao W; Wang M; Shi X
Appl Immunohistochem Mol Morphol; 2021 Aug; 29(7):541-545. PubMed ID: 33958523
[TBL] [Abstract][Full Text] [Related]
15. CDX2 co-localizes with liver-intestine cadherin in intestinal metaplasia and adenocarcinoma of the stomach.
Ko S; Chu KM; Luk JM; Wong BW; Yuen ST; Leung SY; Wong J
J Pathol; 2005 Apr; 205(5):615-22. PubMed ID: 15732140
[TBL] [Abstract][Full Text] [Related]
16. Clinicopathological significant and prognostic influence of cadherin-17 expression in gastric cancer.
Ito R; Oue N; Yoshida K; Kunimitsu K; Nakayama H; Nakachi K; Yasui W
Virchows Arch; 2005 Oct; 447(4):717-22. PubMed ID: 16044349
[TBL] [Abstract][Full Text] [Related]
17. Value of SATB2, ISL1, and TTF1 to differentiate rectal from other gastrointestinal and lung well-differentiated neuroendocrine tumors.
Zhao LH; Chen C; Mao CY; Xiao H; Fu P; Xiao HL; Wang G
Pathol Res Pract; 2019 Jul; 215(7):152448. PubMed ID: 31133441
[TBL] [Abstract][Full Text] [Related]
18. PDX-1, CDX-2, TTF-1, and CK7: a reliable immunohistochemical panel for pancreatic neuroendocrine neoplasms.
Chan ES; Alexander J; Swanson PE; Jain D; Yeh MM
Am J Surg Pathol; 2012 May; 36(5):737-43. PubMed ID: 22498824
[TBL] [Abstract][Full Text] [Related]
19. Examination of PHOX2B in adult neuroendocrine neoplasms reveals relatively frequent expression in phaeochromocytomas and paragangliomas.
Lee JP; Hung YP; O'Dorisio TM; Howe JR; Hornick JL; Bellizzi AM
Histopathology; 2017 Oct; 71(4):503-510. PubMed ID: 28464318
[TBL] [Abstract][Full Text] [Related]
20. Aberrant expression of SATB2, CDX2, CDH17 and CK20 in hepatocellular carcinoma: a pathological, clinical and outcome study.
Kmeid M; Lukose G; Hodge K; Cho D; Kim KA; Lee H
Histopathology; 2021 Nov; 79(5):768-778. PubMed ID: 34036629
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
